Lynkuet Side Effects: Common Rates, Serious Warnings, and What to Do

What are the most common Lynkuet side effects?

Below is every common side effect from the FDA label, side by side with the placebo group. That placebo column is the whole point. Many events also happened to women taking a placebo (a dummy capsule with no medicine) — so the number that points to Lynkuet itself is the gap between the two groups.

Lynkuet side-effect rates over 52 weeks (OASIS 3 trial)

These labels group similar symptoms together,which is why rates here can differ from other summaries: “fatigue” includes asthenia (weakness); “dizziness” includes balance problems, presyncope (feeling faint), and vertigo; “somnolence” includes lethargy; “abdominal pain” includes upper and lower stomach discomfort; “rash” includes dermatitis and hives; and “muscle spasms” includes muscle tightness. These are not all possible side effects — tell your clinician about any new or concerning symptom.

Headache had the highest raw rate — but it was nearly as common on placebo. The biggest gaps over placebo were fatigue, dizziness, and drowsiness— exactly why we show both columns instead of dropping a scary list on you with no context.

Two more grounded facts from the label:

• Nausea and acid refluxalso came up in the shorter OASIS 1 and 2 studies (reported in at least 2% of women and more than placebo), though the label doesn’t attach a single 52-week percentage to them.
• The reactions that led women to stop the drug (in at least 1% of the Lynkuet group and more than placebo) were stomach pain (1.6%), fatigue (1.6%), depression (1.6%), and headache (1.3%). Uncommon overall — but if it’s you, it matters, and that’s a real reason to loop in your prescriber rather than push through.

What should I do about a Lynkuet side effect right now?

Level 1 — Track it, and report if it sticks around

Ordinary headache · mild fatigue that doesn’t make things unsafe · mild stomach upset with no liver warning signs · mild diarrhea · mild muscle spasms · mild rash

Write down when it started, how strong it is (0–10), and whether it’s getting better. Tell your clinician if it bothers you, is severe or worsening, or just won’t go away — that’s exactly what the patient leaflet advises.

Level 2 — Don’t drive, and call your clinician soon

Real drowsiness · dizziness · a spinning (vertigo) or faint feeling (presyncope) · fatigue that impairs how you function · new or worsening low mood · a rash, diarrhea, pain, or vomiting that persists

Do not drive or do anything risky while you feel sleepy, dizzy, faint, or foggy. Call your prescriber for advice specific to you — don’t change your dose on your own.

Level 3 — Act now, the way the label says

These are different label instructions, so treat them separately:

Abdominal pain sits in two places at once— it’s both a common labeled reaction anda possible liver-warning sign. If it’s new or unusual, especially with appetite loss, nausea or vomiting, itching, yellowing, pale stools, dark urine, or unusual fatigue, treat it as Level 3: stop and seek care. Otherwise, contact your clinician if it’s severe or persistent.

One honest limit:this page — and the tool below — can tell you which lane a symptom belongs in. It can’t tell you whether Lynkuet actually caused it. Only a clinician who knows your history can do that.

You’re not overreacting by checking whether a new symptom needs attention — that’s exactly the right instinct with any new prescription. And once you’ve handled the symptom in front of you, there’s a bigger question worth answering: whether Lynkuet is even the right path for your situation.

Does Lynkuet make you sleepy or dizzy?

Sleepiness and dizziness deserve their own section, because they’re the effects most likely to touch your daily life — driving, work, staying alert.

Can you drive?

Not while you feel it. The label warns about next-day impairment and says to skip driving and risky activities until the effect wears off. In a computer-based driving-simulation study of 64 healthy women, performance was checked nine hours after a bedtime dose. On average it didn’t cross the impairment threshold — but some women wereimpaired after the very first dose (120 mg or 240 mg), and fewer after five days. Until you know how it hits you, don’t drive or do anything risky while you feel sleepy, dizzy, faint, or off.

When should sleepiness get a phone call?

Skip the “how many days is normal” guessing — the label doesn’t set one. Use function instead. Call if you:

• can’t stay awake normally,
• don’t feel safe to drive,
• are falling or nearly falling,
• feel faint,
• can’t work or care for others, or
• notice it’s getting worse, not better.

Can Lynkuet affect your liver?

Liver monitoring scares people. It shouldn’t scare you off — but it should be respected. Here’s exactly how it works, plus what the FDA’s own liver reviewers found.

Liver monitoring schedule

What the FDA’s liver review actually found

Across the three phase-3 trials, 8 women on Lynkuet vs 2 on placebohad liver-enzyme elevations that met the review threshold, and those were sent to the FDA’s drug-induced liver injury (DILI) team. The DILI team flagged one phase-3 case as possibleliver injury (a woman whose enzymes rose 8× the limit — though the independent liver-safety board disagreed, because it happened very late and five weeks after she had stopped the drug), plus two earlier-phase cases as probable. Here’s the reassuring part: none of these met “Hy’s Law,” the classic red-flag combination that signals serious liver injury, and there were no cases of liver failure.

None of that erases the risk — which is exactly why the blood tests are required, and why “no boxed warning on the current label” is not the same as “no liver risk can ever emerge.” But if the liver question is what’s been scaring you off, that’s the honest, sourced context to weigh.

Which Lynkuet side effects are serious?

In the 52-week trial, serious events occurred in 4.2% of women on Lynkuet vs 1.9% on placebo. The trial’s own investigators didn’t tie any serious event in that study to the drug. But FDA’s reviewers looked deeper, across the whole clinical program, and were more cautious. They judged one seizure related to Lynkuet— in a 58-year-old woman who had had seizures more than 30 years earlier, hospitalized after three seizures at day 46 — and two fainting (syncope) episodes possibly related, including one in the 52-week trial. FDA decided these didn’t need their own separate warning because the numbers were small and the cause wasn’t clear-cut, but they’re a real reason the label warns about drowsiness, next-day impairment, and seizures.

1. Daytime impairment (nervous-system effects)

About 12% vs 3.5% on placebo. Don’t drive while affected. Call if it’s substantial or lasting.

2. Liver-enzyme elevations

Required testing, plus the warning-sign list that means stop. Covered in the liver section above.

3. Pregnancy loss

Pregnancy is a contraindication (a hard no). Animal studies point to a risk of pregnancy loss or stillbirth; there’s no human pregnancy data. If you could become pregnant, the label says to exclude pregnancy before starting, use effective birth control during treatment and for 2 weeks after stopping, and test if pregnancy is suspected. If you become pregnant, stop and call your clinician right away.

4. Seizures

One woman with a decades-old seizure history had a seizure in the trials, judged related by both the investigator and FDA. Rat studies also showed convulsions, and the drug’s chemistry gives a plausible mechanism. The label says use caution if you have a seizure history or a condition that lowers your seizure threshold — not that everyone with a distant history is barred. A seizure or loss of consciousness is emergency care.

Photosensitivity (uncommon but worth noting)

Mild-to-moderate sun sensitivity occurred in 0.5% on Lynkuet vs 0.1% on placebo, and it could start on day 1 or as late as day 290. Most cases resolved while women kept taking it; one led to stopping. If your skin reacts to sun in a new way, tell your clinician.

How long do Lynkuet side effects last — and when can they start?

What did the 52-week Lynkuet study actually show?

The study, at a glance

The safety headline numbers

• Any medical problem during treatment (whatever the cause): 70.0% on Lynkuet vs 61.1% on placebo.
• Problems the researchers linked to the drug: 30.4% vs 14.6% — and about 90% of all events in the Lynkuet group were mild or moderate.
• Stopped the drug because of a side effect: 12.5% vs 4.1%.
• Serious events:4.2% vs 1.9% — with the causality nuance covered in the serious side effects section.

One detail worth understanding: the most common problems “during treatment” included headache and COVID-19. COVID shows up because this was a year-long study during the pandemic — a clean example of why “happened during treatment” isn’t the same as “caused by the drug.” The effects the researchers most often linked to Lynkuet itself were sleepiness, fatigue, and headache.

The uterine-lining question

Across the OASIS trials, biopsies found no endometrial (uterine lining) cancers. The current label does report two OASIS 3 cases of endometrial hyperplasia (overgrowth) without atypia, and across all three trials the overall rate of endometrial abnormalities was 0.8% (4 of 477 biopsies)— which the label describes as in line with the expected background rate. And to restate a reassuring anchor: there were no deaths across the elinzanetant studies.

What the study can’t tell you

• How it performs in women outside the enrolled ages, backgrounds, or health profiles
• Rare side effects that only surface across far more people
• Safety beyond the studied window
• How it truly compares head-to-head with Veozah or hormone therapy — because it wasn’t tested against them
• Whether results apply the same to women who were excluded from the trial

Who should not take Lynkuet, and who needs extra caution?

The label uses different levels of “no,” so we will too — because the difference matters.

What drugs, foods, and supplements interact with Lynkuet?

We’re deliberately not publishing an “exhaustive” interaction list — those go stale and give false confidence. The reliable move is a live check of your list with a pharmacist.

How does Lynkuet compare to Veozah?

The lighter lab schedule is genuinely more convenient. But don’t read it as proof Lynkuet is safer overall. Veozah did not launch problem-free — it shipped in 2023 with a liver-enzyme warning and required liver testing; the serious cases surfaced later in real-world use, prompting a boxed warning in December 2024. Lynkuet is new enough that its own real-world story is still being written.

Full Veozah vs Lynkuet comparison →  ·  All non-hormonal menopause options →

Frequently asked questions about Lynkuet side effects

Before you go

If you strip away every link on this page, our goal was simple: give you the clearest, most honest picture of Lynkuet’s side effects anywhere — real rates, the actual FDA review, and a straight answer about what to do with the symptom in front of you. Non-hormonal doesn’t mean risk-free. But for the right woman, with the liver tests done and the warning signs known, it’s a legitimate option worth an informed conversation.

Still not sure which HRT program is right for you? Take our free matching quiz.

The HRT Index Verification Standardis our documented process for checking published claims, separating FDA-approved from compounded options, verifying details that change, and re-checking them on a fixed schedule. This is a medication-safety page — it does not score Lynkuet or any provider.

Found an outdated label detail or a number that needs updating? Report a correction — we date every correction.